Equities Analysts Offer Predictions for MIST Q3 Earnings

Key Points

• HC Wainwright has lowered its Q3 2025 EPS estimate for Milestone Pharmaceuticals to ($0.14) from a previous estimate of ($0.10), while maintaining a "Buy" rating with a target price of $5.00.
• Milestone Pharmaceuticals missed analysts' consensus with reported Q2 earnings of ($0.20) EPS against an estimate of ($0.18) EPS.
• Institutional investors hold 86.18% of Milestone Pharmaceuticals' stock, with notable increases in positions from firms like Creative Planning and XTX Topco Ltd.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - HC Wainwright dropped their Q3 2025 EPS estimates for Milestone Pharmaceuticals in a report released on Tuesday, August 12th. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($0.14) per share for the quarter, down from their prior forecast of ($0.10). HC Wainwright currently has a "Buy" rating and a $5.00 target price on the stock. The consensus estimate for Milestone Pharmaceuticals' current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals' Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.66) EPS, FY2027 earnings at ($0.71) EPS, FY2028 earnings at $0.02 EPS and FY2029 earnings at $0.23 EPS.

Milestone Pharmaceuticals Price Performance

Shares of NASDAQ MIST traded down $0.03 during midday trading on Friday, reaching $1.67. The stock had a trading volume of 1,337,984 shares, compared to its average volume of 1,738,520. The stock has a 50-day moving average of $1.71 and a 200-day moving average of $1.59. The company has a debt-to-equity ratio of 4.06, a quick ratio of 4.97 and a current ratio of 4.97. The company has a market capitalization of $89.28 million, a price-to-earnings ratio of -1.99 and a beta of 0.52. Milestone Pharmaceuticals has a 12-month low of $0.63 and a 12-month high of $2.75.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02).

Hedge Funds Weigh In On Milestone Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Bay Rivers Group purchased a new position in Milestone Pharmaceuticals during the second quarter valued at $28,000. Creative Planning grew its stake in Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company's stock valued at $45,000 after acquiring an additional 10,000 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Milestone Pharmaceuticals during the fourth quarter valued at $73,000. XTX Topco Ltd purchased a new position in Milestone Pharmaceuticals during the fourth quarter valued at $80,000. Finally, Raymond James Financial Inc. grew its stake in Milestone Pharmaceuticals by 30.1% during the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company's stock valued at $84,000 after acquiring an additional 10,000 shares in the last quarter. 86.18% of the stock is owned by hedge funds and other institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.